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Objective: To study the effect of lipoteichoic acid (LTA) and 5-FU on the expression of
caspase-3, EGFR, TGF-a proteins of tumor tissue of H22 cancer bearing mice and its
anti-tumor mechanism.
Methods: A total of 40 SPF grade Kunming mice were selected to establish H22 liver
cancer model, and then the mice were divided into 4 groups at randomwith ten mice in each
group. Group A was given saline lavage treatment, Group B was treated with 5-FU by
intraperitoneal injection, Group C was treated with LTA by lump body injection; Group D
was treated with LTA by lump body injection and 5-FU by intraperitoneal injection. Two
weeks after the treatment, the mice in each group were executed and the tumor tissue was
stripping and weighted, and the tumor growth inhibition ratio was calculated. Then the
tumor tissue was processed for conventional embedding, sectioned to observe the
expression of caspase-3, EGFR, TGF-a by immunohistochemical staining method.
Results: The tumor inhibitory rate o f Group D was signiﬁcantly higher than Groups B
and C (P < 0.05); B, the tumor inhibitory rate o f Group B had no statistical difference
compared with Group C (P > 0.05). The IDO values of TGF-a, EGFR proteins in Groups
B, C, D mice tumor tissue were signiﬁcantly lower than that in group A (P < 0.05); while
IDO value of caspase-3 in Groups B, C, D group mice tumor tissue was signiﬁcantly
higher than that in Group A (P < 0.05). The IDO value of TGF-a, EGFR in Group D
mice tumor tissue were signiﬁcantly lower than that in Groups B and C; While IDO value
of aspase-3 in Group D was signiﬁcantly higher than that in Groups B and C (P < 0.05).
Conclusions: LTA combined with 5-FU can effectively inhibit the tumorigenesis of H22
tumor bearing mice, increase the caspase-3 protein expression, inhibit TGF-a and EGFR
protein expression, further promote tumor cell apoptosis and play a synergistic antitumor
effect.1. Introduction
Primary liver cancer is one of clinical common malignant
tumors, the morbidity showed a rising trend year by year inrecent years [1]. According to statistics [2], about 42% of global
new liver cancer patients are in China. Liver cancer has
become the second leading cause of death in China's tumor
patients with serious damage to their life and health. As
continuous research on liver cancer diagnosis, treatment and
prognosis conducted by many modern scholars, the
therapeutic schedule has transformed from a single surgery
treatment mode to mode of surgery supplemented with part
treatment and combination with a variety of methods [3].
Chemotherapy is an important mean to prolong the life of
patients with liver cancer and has curative effect. But liver
cancer has a low sensitivity for most of chemotherapeutic
drugs, poor effect of chemotherapy alone, and the larger
toxic and adverse reaction, moreover, it has no obviousopen access article under the CC BY-NC-ND
Table 1
Comparison of tumor inhibitory rate among groups mice.
Groups n Tumor
volume (cm3)
Tumor
weight (g)
Tumor
inhibitory rate
Group A 10 1.79 ± 0.22 2.15 ± 0.21 –
Group B 10 0.61 ± 0.11*# 0.35 ± 0.20*# 46.19
Group C 10 0.44 ± 0.12* 0.97 ± 0.21* 54.62
Group D 10 0.11 ± 0.71*#△ 0.62 ± 0.61*#△ 71.82
*: Compared with Group A, P < 0.05; #: Compared with Group C,
P < 0.05; △: Compared with Group B, P < 0.05.
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with liver cancer. Biﬁdobacteria are important physiologic
bacteria in human intestinal and the major effective
component is lipoteichoic acid (LTA). Studies have
conﬁrmed that [4], LTA can signiﬁcantly inhibit tumor cell
proliferation, promote apoptosis, improve the immune
function of body on the tumor, and has signiﬁcant inhibitory
effect on a wide variety of tumor cells. 5-FU, clinical
commonly used chemotherapy drugs, has become the main
chemotherapy drug for digestive system tumor and has the
curative effect. In this study to explore the tumor suppression
effect of LTA combined with 5-FU, SD mice were selected to
establish H22 liver cancer model, then treated with LTA and 5-
FU, and the tumor suppression effect and mechanism of action
was observed for providing clinical laboratory data for its
clinical application.
2. Materials and methods
2.1. Experimental animals
Forty SPF kunming mice aged between 8 and 12 weeks,
weighting 18–22 g, were selected, provided by Beijing Huafu-
kang Biological Technology co., LTD. The mice received food
and water ad libitum under the temperature of (23 ± 3) C. The
experimental process strictly followed the Regulations on the
Administration of Experimental Animals to deal with experi-
mental animals.
2.2. Experimental drugs and instruments
LTA was isolated and puriﬁed from biﬁdobacteria ado-
lescentis passage in Balb/c mice for breeding according to the
method of literature [5]. 5-FU injection, provided by Nanjing
Jiancheng Biological Engineering Institute, was prepared with
normal saline into 3 mg/mL, stored for future use. H22 tumor
strains were obtained from the cell bank of Shanghai Institute of
Biochemistry and Cell Biology, Chinese Academy of Sciences.
Rabbit anti-mouse caspase 3, EGFR, TGF-a ready-to-use
monoclonal antibody and DAB chromogenic liquid were pur-
chased from Beijing Zhongshan Company. BL420 multichannel
physiologic recorder, BI-2000 immunohistochemical analysis
system (Chengdu), Olympus BH- type 2 microscope (Japan)
were used.
2.3. Establishment of H22 tumor cancer mice model
Extraction of H22 tumor ascites in Balb/c mice, mixed with
normal saline by 1:3, was thoroughly homogenized and diluted
to 4 × 107 cells/mL. A total of 0.2 mL of H22 tumor ascites was
used for axillary vaccination in experimental mice, the whole
process from the extraction of ascites to transplant completion
was within 2 h. After vaccination 40 experimental mice were
randomly divided into A, B, C, D four groups, each group of 10
mice. Group A was given 0.4 mL of normal saline for lavage,
once a day. Group B was given 25 mg/g of 5-FU by intraperi-
toneal injection every other day; Group C was treated with
150 mg of LTA by lump body injection every other day; Group
D was given LTA by lump body injection combined with 5-FU
by intraperitoneal injection with the same dosage and usage with
Groups B and C. Four groups of mice were treated for two
weeks.2.4. Observation items
Groups of mice were executed on the next day after the treat-
ment. Stripped intact tumor tissue and blotted up with ﬁlter paper,
weighted and calculated average weight and area of tumor tissue,
and tumor inhibitory rate. After weighing, the tumor issue was
conventional embedding, sectioning, immunohistochemical stain-
ing to observe the expression of caspase 3, EGFR and TGF-a pro-
teins. The results judgment [6]: caspase 3 protein positive expression
shows yellow or brown granules, mainly expressed in the
cytoplasm; EGFR protein expression shows yellow and brown
granules, mainly expressed in the cytoplasm and cell membrane;
TGF-a protein positive expression shows yellow and brown
granules, mainly expressed in the cytoplasm and cell membrane.
2.5. Statistical analysis
Data was analyzed by SPSS 10.0 software, and expressed as
mean ± SD. They were analyzed by using the One-way ANOVA
among groups. P < 0.05 was considered as statistically signiﬁ-
cant difference.
3. Results
3.1. Comparison of tumor inhibitory rate among groups
mice
Tumor volume and weight of Groups B, C, D was signiﬁ-
cantly lower than that of Group A (P < 0.05). Tumor volume
and weight of Groups B, D was signiﬁcantly lower than that of
Group C (P < 0.05). Tumor volume of Group D was signiﬁ-
cantly lower than that of Group B (P < 0.05), while tumor
weight was signiﬁcantly higher than group B (P < 0.05). Tumor
inhibitory rate of Group D was signiﬁcantly higher than that of
Groups B and C (P < 0.05). The results were shown in Table 1.
3.2. Expression of caspase-3, EGFR, TGF-a proteins in
tumor issue
The expression of caspase 3 protein in the tumor tissue of
Groups B, C, D mice was signiﬁcantly higher than that in Group
A (P < 0.05), while the expression of EGFR and TGF-a proteins
in Groups B, C, D was signiﬁcantly lower than that in Group A
(P < 0.05). Caspase 3 protein expression in Groups B and D was
signiﬁcantly higher than that in Group C (P < 0.05), while the
expression of EGFR and TGF-a was signiﬁcantly lower than
that in Group C (P < 0.05). Expression of caspase 3 protein in
Group D was signiﬁcantly higher than in Group B (P < 0.05),
while EGFR, TGF-a expression was signiﬁcantly lower than in
Group B (P < 0.05). The results were shown in Table 2.
Table 2
Expression of caspase-3, EGFR, TGF-a proteins in tumor issue of groups mice (IOD value).
Groups n Caspase-3 EGFR TGF-a
Group A 10 2 280 901.7 ± 3 575 753.0 1723.67 ± 41.35 1845.43 ± 49.26
Group B 10 7 028 868.2 ± 3 048 702.8*# 855.76 ± 55.09*# 866.76 ± 54.99*#
Group C 10 5 867 940.6 ± 2 180 526.4* 1008.24 ± 19.47* 1086.24 ± 21.47*
Group D 10 8 998 374.1 ± 2 959 586.5*#△ 697.24 ± 35.67*#△ 697.24 ± 36.67*#△
*Compared with Group A, P < 0.05; #: Compared with Group C, P < 0.05; △: Compared with Group B, P < 0.05.
Figure 1. Expression of caspase-3, EGFR, TGF-a proteins in tumor tissue biopsies of different groups.
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TGF-a proteins expression in tumor issue biopsies
Microscopically, caspase-3 was more expression in the
cytoplasm, which in group D expressed the highest; EGFR,
TGF-a was expression in the cytoplasm and cell membrane, and
mainly in cell membrane expression, expression of Groups C, B
and D were signiﬁcantly lower than that of Group A. The results
were presented in Figure 1.
4. Discussion
Liver cancer is a clinically common malignant tumor, and
the average age attacked by this disease was 44. It has a high
malignant degree, developed fast, if not treated in time, theaverage survival time was only half a year, seriously affect the
quality of life of patients [7]. The early stage of liver cancer
has no obvious symptoms, once found, about one third of
patients have been in advanced stage [8]. Liver cancer should
be treated individualized with comprehensive treatment
according to different stages of liver cancer. Surgery is the
ﬁrst choice for liver cancer treatment. For cancer cannot be
removed by surgery after surgical exploration, or as follow-
up treatment of a tumor palliative resection, comprehensive
treatment with radiation as the major one can be used. But the
solution has larger toxic and adverse reactions and greatly
inﬂuent the patient's life [9]. Therefore, it is a clinically urgent
issue to be solved that looks for an effective treatment
schedule to improve the quality of life and survival time of
the patients.
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chemotherapy regimens drug for digestive system tumor. It has
an obvious effect on the proliferation of tumor cells, but it has
limited targeting property, the sensitivity declines after repeat-
edly use and lager side effects, which limit its use for a long time
[9–12]. LTA, isolated and puriﬁed from biﬁdobacteria
adolescentis, is a kind of linear glycerol phosphate amphoteric
polymer related to the adhesion [13]. Studies have conﬁrmed
that [14–16], LTA can inhibit the growth of a variety of tumor
cells. It is safe with non-toxic side effects and can be long-
term use. At present, the main anti-tumor mechanism focused
on two aspects, i.e. direct tumor suppression and improving the
antitumor immunity of patients. In this study, after the treatment
the tumor weight and volume in Groups B and C was signiﬁ-
cantly lower than that in Group A (P < 0.05). It proved that both
the two drugs have a certain tumor suppression effect. No sta-
tistical difference was found in the inhibitory rate these two
groups (P < 0.05), it indicated that both the two drugs has
similar tumor suppression effect. After treatment inhibitory rate
of tumor issue in Group D mice was signiﬁcantly higher than in
Groups B and C (P < 0.05), suggesting that the curative effect of
combination of LTA and 5-FU in tumor suppression is signiﬁ-
cantly better than alone.
In recent years, the relationship between the incidence of liver
cancer and the cytokines has become the research focus, but
research reports on TGF-a are relatively few [17]. TGF-a is a
polypeptide composed of 50 amino acid, played a special role in
regulating the growth of normal cells and the transformation of
abnormal cells [18]. EGFR is the expression product of proto-
oncogene c-erbB-1. It is widely distributed in mammalian
epithelial cell membrane and vascular tissue, and plays an
important role in regulating cell proliferation and activation [19].
Studies have found that [20], TGF-a, EGFR can express in liver
cancer tissues at the same time. Moreover, the excessive
expression closely associated with the onset of cancer of the
liver, and there is a signiﬁcant positive correlation between these
two expressions. The results of this study showed that the
expression of EGFR and TGF-a proteins in Groups B, C, D after
treatment was signiﬁcantly lower than that in Group A
(P < 0.05); EGFR, TGF-a expression in Group D was
signiﬁcantly lower than in Groups B and C (P < 0.05). This
manifested that combined treatment can effectively inhibit the
over expression of TGF-a and EGFR, inhibit tumor cell
proliferation, thus achieve the therapeutic effect of tumor
suppression. Caspase, according to its role in cell apoptosis, can
be divided into two kinds, enzymes for initiating and effective
enzymes, which is the great discovery in the research of
apoptosis in molecular biology in recent years [21]. In caspase,
caspase 3 is an important effective protein lyase, and plays an
important role in the process of tumor cell apoptosis [22,23]. The
results of this study showed that after the treatment the
expression of caspase 3 in Group D was signiﬁcantly higher than
the other three (P < 0.05), suggesting that the LTA combined
with 5-FU can improve the expression of caspase 3, promote tu-
mor cell apoptosis, and thus play a synergistic antitumor effect.
According to the results of this study LTA combined with 5-
FU can inhibit the over expression of TGF-a and EGFR
expression, improve the expression of caspase 3, thus inhibit
tumor cell proliferation and promote tumor cell apoptosis.
Therefore, LTA combined with 5-FU has remarkable synergistic
antitumor effects.Conﬂict of interest statement
We declare that we have no conﬂict of interest.
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